DelveInsight’s, “Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request a sample and discover the recent advances in Ovarian Cancer @ Ovarian Cancer Pipeline Outlook Report

 

Key Takeaways from the Ovarian Cancer Pipeline Report

• August 2024:- AGO Research GmbH- This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.
• August 2024:- Suzhou Suncadia Biopharmaceuticals Co., Ltd.- A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator’s Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer. This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator’s choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
• DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
• The leading Ovarian Cancer Companies working in the market include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Promising Ovarian Cancer Therapies in the various stages of development include SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others. 

 

Learn more about Ovarian Cancer in clinical trials @ Ovarian Cancer Drugs

 

Ovarian Cancer Overview

Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. Ovarian cancer can be further classified into two subtypes- Type I or Type II tumors, the latter being a more fatal variant, thought to be caused by continuous ovarian cycles leading to inflammation and endometriosis. Type I tumor includes low-grade serous, endometrioid, clear-cell, and mucinous carcinomas, with the rare subtypes being seromucinous and Brenner tumors. Type I tumors mostly arise from atypical proliferative (borderline) tumors.

 

Ovarian Cancer Emerging Drugs Profile

• Atezolizumab: Genentech
• Tisotumab Vedotin: Genmab
• SON-1010: Sonnet Biotherapeutics
• DS-6000a: Daiichi Sankyo Company

  

Discover more about Ovarian Cancer in development @ Ovarian Cancer Clinical Trials

 

Ovarian Cancer Therapeutics Assessment

There are approx. 180+ Ovarian Cancer companies which are developing the Ovarian Cancer therapies. The Ovarian Cancer companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Ovarian Cancer pipeline report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Ovarian Cancer Companies

Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.

 

To know more about Ovarian Cancer, visit @ Ovarian Cancer Segmentation

 

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Ovarian Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

For further information on the Ovarian Cancer Pipeline Therapeutics, reach out @ Ovarian Cancer Products Development

 

Scope of the Ovarian Cancer Pipeline Report

• Coverage- Global
• Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.

 

 Table of Content

1. Introduction
2. Executive Summary
3. Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ovarian Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tisotumab Vedotin: Genmab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS-6000a: Daiichi Sankyo Company
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ovarian Cancer Key Companies
21. Ovarian Cancer Key Products
22. Ovarian Cancer- Unmet Needs
23. Ovarian Cancer- Market Drivers and Barriers
24. Ovarian Cancer- Future Perspectives and Conclusion
25. Ovarian Cancer Analyst Views
26. Ovarian Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/